The construction of a neobladder, a solution used in 90% of bladder cancer operations at MD Anderson Madrid – Hospiten Published on 09/05/2022 Multidisciplinary management and rapid access to innovative therapies maximize the chances of cure and recovery for patients with bladder cancer
Immediate access to innovation in kidney cancer treatments, essential for patient survival Published on 08/03/2022 MD Anderson Madrid – Hospiten offers the possibility of access to clinical trials and surgery with the Da Vinci robot for patients with kidney cancer, one of the 15 most common tumors in Spain
The DIPCAN study seeks to change the way metastatic cancer is treated in Spain thanks to the integration of clinical, genomic, anatomic pathology and radiology image data from 2,000 patients Published on 22/02/2022 Participating patients will have free access to the genomic study of their tumor, both in the biopsy sample and in blood, to a full-body MRI and to digitization of anatomic pathology images
MD Anderson Madrid – Hospiten inaugurates their Phase I Clinical Trials Unit, one of the largest in Spain and Europe dedicated to the first phase of research Published on 03/11/2021 Advised directly from Houston, the unit will focus on research into the most promising cancer drugs in clinical development worldwide. It is estimated that more than 40 clinical studies in phase I will be investigated simultaneously
A combination of chemotherapy and immunotherapy for the first time shows superiority over chemotherapy alone in metastatic bladder cancer Published on 08/10/2019 Dr. Enrique Grande, head of the Medical Oncology Service at MD Anderson Madrid – Hospiten, is co-chair of the IMvigor130 clinical trial, which has evaluated the efficacy of this combination in front line treatment